DENVER, Colo. (247marketnews.com) — Nexalin Technology (NASDAQ:NXL) is putting a major commercial marker on the board with a definitive exclusive distribution and local manufacturing agreement covering Brazil and six additional South American markets. The 10-year agreement with Inovanexa Medical Technologies gives the distributor exclusive rights across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, representing a combined population of more than 300 million people. For Nexalin, the development shifts the story beyond clinical development and toward commercialization of its ANVISA-approved Nexalin Sync
non-invasive neurostimulation technology.
The agreement starts with a binding order for 10 Nexalin Sync devices, with five scheduled for immediate delivery, followed by a clinical pilot in Brazil targeted to launch within 90 days. The broader commercialization framework calls for an initial 100-device program and establishes a pathway for larger government and private-sector transactions. Nexalin also expects the arrangement to create recurring economics through local manufacturing: after the first 30 devices are purchased, the distributor is required to establish a Brazil-based manufacturing facility at its own expense, while Nexalin retains ownership of its intellectual property and receives compensation tied to locally manufactured devices and disposable electrodes.
The company is leaning heavily on groundwork already completed in Brazil. Nexalin says its Sync device has received ANVISA approval for anxiety, depression and insomnia, while a clinical trial conducted at the Institute of Psychiatry at the University of São Paulo reported a 77.8% anxiety response rate. The company is also positioning Brazil as a potential template for broader international expansion, with the new agreement giving its technology access to private healthcare providers as well as government tenders, public hospitals and universities throughout the covered territory.
“This Agreement is the commercial culmination of everything we have methodically built in Brazil — and the launch pad for all of South America,” Nexalin CEO Mark White said. He described the arrangement as an “inflection point” in the company’s transition toward a revenue-producing global distribution model, while emphasizing that the structure is designed to be capital-light for Nexalin because the distributor is responsible for manufacturing, regulatory compliance, importation and marketing costs.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.